-
公开(公告)号：US09310383B2
公开(公告)日：2016-04-12
申请号：US14729343
申请日：2015-06-03
发明人： William F. Goure , Renee C. Gaspar , Alexander McCampbell , Mary J. Savage , Paul J. Shughrue , Fubao Wang , Weirong Wang , Abigail L. Wolfe , Ningyan Zhang , Wei-Qin Zhao , Min Xu
IPC分类号： C07K16/18 , G01N33/577 , G01N33/68
CPC分类号： G01N33/6896 , C07K16/18 , C07K2317/24 , C07K2317/55 , C07K2317/565 , C07K2317/76 , C07K2317/92 , C07K2317/94 , G01N2333/4709 , G01N2800/2821
摘要： This invention is a selective Aβ oligomer kit and immunoassay method capable of reliably and sensitively detecting Aβ oligomers in a biological sample of a patient. In one embodiment the inventive assay uses a pair of anti-Aβ oligomer antibodies, as capture and detection antibodies, to detect and quantify Aβ oligomers. The method can be used to differentiate Alzheimer's disease (AD) patients from non-AD patients and/or to stratify AD patients according to the severity of their disease.
-
2.发明授权Method for treating a disease associated with soluble, oligomeric species of amyloid beta 1-42 有权治疗与淀粉样β1-42的可溶性低聚物种相关的疾病的方法公开(公告)号：US09320793B2
公开(公告)日：2016-04-26
申请号：US13693362
申请日：2012-12-04
发明人： William F. Goure , Franz F. Hefti , Renee C. Gaspar , Paul J. Shughrue , Fubao Wang , Weirong Wang , Ningyan Zhang , Wei-Qin Zhao , Alexander McCampbell , Min Xu
IPC分类号： A61K39/395 , C07K16/18 , A61K45/06 , A61K39/00
CPC分类号： A61K39/3955 , A61K45/06 , A61K2039/505 , C07K16/18 , C07K2317/24 , C07K2317/55 , C07K2317/565 , C07K2317/76 , C07K2317/90 , C07K2317/92 , C07K2317/94
摘要： This invention is a method and kit for treating a disease associated with, or resulting from, the accumulation of soluble oligomer amyloid beta 1-42 using an antibody, or antibody fragment thereof, that has a higher affinity for amyloid beta 1-42 oligomers than for amyloid beta 1-42 monomer, amyloid beta 1-40 monomer, plaques and amyloid beta fibrils and, optionally, a tau therapeutic or an inhibitor of amyloid beta production or aggregation.
摘要翻译： 本发明是一种用于治疗与可溶性低聚物淀粉样蛋白β1-42的积累相关或由其引起的疾病的方法和试剂盒，其使用对淀粉样蛋白β1-42寡聚体具有较高亲和力的抗体或其抗体片段， 淀粉样蛋白β1-42单体，淀粉样蛋白β1-40单体，斑块和淀粉样蛋白β原纤维，以及任选的tau治疗剂或淀粉样β生成或聚集抑制剂。
-
3.发明申请公开(公告)号：US20150260731A1
公开(公告)日：2015-09-17
申请号：US14729343
申请日：2015-06-03
发明人： William F. Goure , Renee C. Gaspar , Alexander McCampbell , Mary J. Savage , Paul J. Shughrue , Fubao Wang , Weirong Wang , Abigail L. Wolfe , Nigyan Zhang , Wei-Qin Zhao
CPC分类号： G01N33/6896 , C07K16/18 , C07K2317/24 , C07K2317/55 , C07K2317/565 , C07K2317/76 , C07K2317/92 , C07K2317/94 , G01N2333/4709 , G01N2800/2821
摘要： This invention is a selective Aβ oligomer kit and immunoassay method capable of reliably and sensitively detecting Aβ oligomers in a biological sample of a patient. In one embodiment the inventive assay uses a pair of anti-Aβ oligomer antibodies, as capture and detection antibodies, to detect and quantify Aβ oligomers. The method can be used to differentiate Alzheimer's disease (AD) patients from non-AD patients and/or to stratify AD patients according to the severity of their disease.
摘要翻译： 本发明是一种选择性的 低聚物试剂盒和免疫测定法，能够可靠而灵敏地检测A＆bgr; 患者生物样品中的低聚物。 在一个实施方案中，本发明的测定使用一对抗A＆bgr; 低聚物抗体作为捕获和检测抗体，用于检测和定量A＆bgr; 低聚物。 该方法可用于区分阿尔茨海默病（AD）患者和非AD患者和/或根据其疾病的严重程度分层AD患者。
-
4.发明申请METHOD FOR TREATING A DISEASE ASSOCIATED WITH SOLUBLE, OLIGOMERIC SPECIES OF AMYLOID BETA 1-42 有权用于治疗与可溶性疾病相关的疾病的方法，低分子量的AMYLOID BETA 1-42公开(公告)号：US20130089537A1
公开(公告)日：2013-04-11
申请号：US13693362
申请日：2012-12-04
发明人： William F. Goure , Franz F. Hefti , Renee C. Gaspar , Paul J. Shughrue , Fubao Wang , Weirong Wang , Ningyan Zhang , Wei-Qin Zhao
IPC分类号： A61K39/395 , A61K45/06 , C07K16/18
CPC分类号： A61K39/3955 , A61K45/06 , A61K2039/505 , C07K16/18 , C07K2317/24 , C07K2317/55 , C07K2317/565 , C07K2317/76 , C07K2317/90 , C07K2317/92 , C07K2317/94
摘要： This invention is a method and kit for treating a disease associated with, or resulting from, the accumulation of soluble oligomer amyloid beta 1-42 using an antibody, or antibody fragment thereof, that has a higher affinity for amyloid beta 1-42 oligomers than for amyloid beta 1-42 monomer, amyloid beta 1-40 monomer, plaques and amyloid beta fibrils and, optionally, a tau therapeutic or an inhibitor of amyloid beta production or aggregation.
摘要翻译： 本发明是一种用于治疗与可溶性低聚物淀粉样蛋白β1-42的积累相关或由其引起的疾病的方法和试剂盒，其使用对淀粉样蛋白β1-42寡聚体具有较高亲和力的抗体或其抗体片段， 淀粉样蛋白β1-42单体，淀粉样蛋白β1-40单体，斑块和淀粉样蛋白β原纤维，以及任选的tau治疗剂或淀粉样β生成或聚集抑制剂。
-
5.发明申请METHOD FOR TREATING A DISEASE ASSOCIATED WITH SOLUBLE, OLIGOMERIC SPECIES OF AMYLOID BETA 1-42 审中-公开用于治疗与可溶性疾病相关的疾病的方法，低分子量的AMYLOID BETA 1-42公开(公告)号：US20150320860A1
公开(公告)日：2015-11-12
申请号：US14648316
申请日：2013-12-04
发明人： William F. Goure , Franz F. Hefti , Renee C. Gaspar , Paul J. Shughrue , Fubao Wang , Weirong Wang , Ningyan Zhang , Wei-Qin Zhao
IPC分类号： A61K39/395 , A61K45/06 , C07K16/18
CPC分类号： A61K39/3955 , A61K45/06 , A61K2039/505 , C07K16/18 , C07K2317/24 , C07K2317/55 , C07K2317/565 , C07K2317/76 , C07K2317/90 , C07K2317/92 , C07K2317/94
摘要： This invention is a method and kit for treating a disease associated with, or resulting from, the accumulation of soluble oligomer amyloid beta 1-42 using an antibody, or antibody fragment thereof, that has a higher affinity for amyloid beta 1-42 oligomers than for amyloid beta 1-42 monomer, amyloid beta 1-40 monomer, plaques and amyloid beta fibrils, wherein the antibody is in combination with a tau therapeutic or an inhibitor of amyloid beta production or aggregation.
摘要翻译： 本发明是一种用于治疗与可溶性低聚物淀粉样蛋白β1-42的积累相关或由其引起的疾病的方法和试剂盒，其使用对淀粉样蛋白β1-42寡聚体具有较高亲和力的抗体或其抗体片段， 对于淀粉样β1-42单体，淀粉样β1-40单体，噬菌斑和淀粉样蛋白β原纤维，其中抗体与tau治疗剂或淀粉样蛋白β生产或聚集的抑制剂组合。
-
公开(公告)号：US09309309B2
公开(公告)日：2016-04-12
申请号：US14326974
申请日：2014-07-09
发明人： Renee C. Gaspar , Paul J. Shughrue , Fubao Wang , Weirong Wang , Ningyan Zhang , Wei-Qin Zhao , Min Xu , Alexander McCampbell
IPC分类号： A61K39/395 , C07K16/18 , A61K45/06 , A61K39/00
CPC分类号： C07K16/18 , A61K39/3955 , A61K45/06 , A61K2039/505 , C07K2317/24 , C07K2317/55 , C07K2317/565 , C07K2317/64 , C07K2317/76 , C07K2317/90 , C07K2317/92 , C07K2317/94
摘要： The present invention relates to antibodies that bind amyloid β-derived diffusible ligands, also known as ADDLs. The antibodies of the invention are selective for ADDLs, can penetrate the brain, and are useful in methods of detecting ADDLs and diagnosing Alzheimer's disease. The present antibodies also block binding of ADDLs to neurons, assembly of ADDLS, and tau phosphorylation and are there useful in methods for the preventing and treating diseases associated with ADDLs.
摘要翻译： 本发明涉及结合淀粉样蛋白和衍生的扩散配体（也称为ADDL）的抗体。 本发明的抗体对ADDL是有选择性的，可以穿透脑，并且可用于检测ADDL和诊断阿尔茨海默病的方法。 本抗体还阻断ADDL与神经元的结合，ADDLS的组装和tau磷酸化，并且在用于预防和治疗与ADDL相关的疾病的方法中是有用的。
-
公开(公告)号：US20150023952A1
公开(公告)日：2015-01-22
申请号：US14326974
申请日：2014-07-09
发明人： Renee C. Gaspar , Paul J. Shughrue , Fubao Wang , Weirong Wang , Ningyan Zhang , Wei-Qin Zhao , Min Xu , Alexander McCampbell
IPC分类号： C07K16/18
CPC分类号： C07K16/18 , A61K39/3955 , A61K45/06 , A61K2039/505 , C07K2317/24 , C07K2317/55 , C07K2317/565 , C07K2317/64 , C07K2317/76 , C07K2317/90 , C07K2317/92 , C07K2317/94
摘要： The present invention relates to antibodies that bind amyloid β-derived diffusible ligands, also known as ADDLs. The antibodies of the invention are selective for ADDLs, can penetrate the brain, and are useful in methods of detecting ADDLs and diagnosing Alzheimer's disease. The present antibodies also block binding of ADDLs to neurons, assembly of ADDLS, and tau phosphorylation and are there useful in methods for the preventing and treating diseases associated with ADDLs.
摘要翻译： 本发明涉及结合淀粉样蛋白和衍生的扩散配体（也称为ADDL）的抗体。 本发明的抗体对ADDL是有选择性的，可以穿透脑，并且可用于检测ADDL和诊断阿尔茨海默病的方法。 本抗体还阻断ADDL与神经元的结合，ADDLS的组装和tau磷酸化，并且在用于预防和治疗与ADDL相关的疾病的方法中是有用的。
-
-
-
-
-
-
搜索结果
7 条记录 (耗时 0.024 秒)
